Drug Trial Radar · NCT01439074
Mepilex Ag Versus Silver Sulfadiazine in Children and Adults With Burn Injuries.
Last checked: Nov 19, 2026Latest source record: Dec 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
162
Actual
Start
Sep 2011
Primary completion
Sep 2013
Study completion Sep 2013
Sponsor
- Lead sponsor
- Molnlycke Health Care ABIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2011
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose is to compare time to healing using absorbent foam silver dressing (Mepilex Ag) compared to a silver sulfadiazine (SSD) 1% cream in the treatment of partial thickness burn injuries.284 in-patients in 8-12 centres in China will be evaluated. Treatment period will be up to 4 weeks with either Mepilex Ag or SSD.
Conditions
- Burn Injuries
Interventions
Mepilex AgDevice
Dressing
Silver Sulphadiazine Ag creamDrug
A cream used on burnt areas.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to HealingTime frame: 4 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Beijing Children's Hospital
Beijing, China
Changhai Hoospital of Shanghai
Shanghai, China
The 1st People's Hospital of Foshan
Guangdong, Guangdong, China
Guangzhou red Cross Hospital
Guangzhou, Guangdong, China
The First People's Hospital of ZhengZhou
Zhenzhou, Henan, China
The 3rd People's Hospital of Wuxi
Wuxi, Jiangsu, China
Beijing Jishuitan Hospital
Taiyuan, Shanxi, China
Xijing Hospital
XiAn, Shanxi, China
The 2nd affiliated Hospital of KunMing Medical college
Kunming, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.